Provention Bio
United States
188 articles about Provention Bio
-
Provention Bio Announces Leadership Team Expansion
12/20/2021
Provention Bio, Inc. today announced that the Company has appointed Christina Yi as Chief Operations Officer, responsible for manufacturing, supply chain and human resources, and Benedict Osorio as Chief Quality Officer, responsible for all aspects of quality.
-
Provention Bio Announces the Grant of Inducement Awards - Dec 02, 2021
12/2/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to two new employees to purchase an aggregate of 550,000 shares of the Company's common stock.
-
Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway
11/22/2021
Provention Bio, Inc. today provided an update on its ongoing efforts to address U.S. Food and Drug Administration (FDA) considerations cited in the Complete Response Letter (CRL) issued to the Company by the FDA on July 2, 2021.
-
Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development
11/17/2021
Provention Bio, Inc. today announced the appointment of Jan Hillson , M.D., as Senior Vice President of Clinical Development.
-
Provention Bio Puts Type 1 Diabetes to the Test with Pledge Campaign for Diabetes Awareness Month
11/9/2021
Provention Bio, Inc. today announced it's putting type 1 diabetes (T1D) to the test during Diabetes Awareness Month this November.
-
Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development
11/5/2021
Provention Bio, Inc. today announced the appointment of Miguel Sanjuan , Ph.D. as Senior Vice President of Research and Early Development.
-
Provention Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
11/4/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, reported financial results for the third quarter ended September 30, 2021 and provided a business update.
-
Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer
11/4/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that Thierry Chauche will become Chief Financial Officer effective December 1, 2021 and Andrew Drechsler will be retiring, following a career of nearly 30 years in the financial and life sciences industry, most notably, the past four years at Provention Bio.
-
Provention Bio to Report Third Quarter 2021 Financial Results on November 4, 2021
10/28/2021
Provention Bio, Inc. today announced that it will report its third quarter 2021 financial results on Thursday, November 4, 2021 , before the opening of the U.S. financial markets.
-
On Tuesday morning, Provention Bio announced positive interim results from its Phase I PROVENT study of PRV-101.
-
Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
10/26/2021
Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
-
Provention Bio to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021
9/23/2021
Provention Bio, Inc. today announced that management will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021 on Wednesday, September 29, 2021 at 3:20 pm E.T.
-
Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
9/16/2021
Provention Bio, Inc. today announced that management will participate in a fireside chat presentation at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Wednesday, September 22, 2021 at 9:05 am E.T
-
Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission
9/13/2021
Provention Bio, Inc. today provided an update on the status and timing of its ongoing efforts to address FDA considerations cited in the Complete Response Letter (CRL) issued to the Company by the FDA on July 2, 2021.
-
Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
8/5/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, reported financial results for the second quarter ended June 30, 2021 and provided a business update.
-
Provention Bio to Report Second Quarter 2021 Financial Results on August 5, 2021
7/29/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that it will report its second quarter 2021 financial results on Thursday, August 5, 2021, before the opening of the U.S. financial markets.
-
Teplizumab Awarded Innovation Passport in the United Kingdom (UK) for the Delay of Onset of Clinical Type 1 Diabetes in At-risk Individuals
7/12/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that teplizumab, an anti-CD3 monoclonal antibody, was awarded an Innovation Passport for the delay of clinical type 1 diabetes in at-risk individuals.
-
Provention Bio Receives Complete Response Letter (CRL) to Biologics License Application (BLA) for Teplizumab for the Delay of Clinical Type 1 Diabetes (T1D) in At-risk Individuals
7/6/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for the Company's Biologics License Application for teplizumab for the delay of clinical type 1 diabetes in at-risk individuals.
-
The FDA issued Provention a CRL that focuses on a single low-dose pharmacokinetic/pharmacodynamic (PK/PD) bridging study in health volunteers.
-
Ahead of the July Fourth holiday, the U.S. Food and Drug Administration has two PDUFA dates on the calendar. Here’s a look.